Navigation Links
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Date:10/15/2007

< 0.05).

"These diseases are devastating to patients and their loved ones and we are excited to see more and better therapies become available to ease their suffering," said Richard J. Geswell, President, Crohn's & Colitis Foundation of America.

About the ACT Long-Term Extension

Patients with moderate to severe UC, defined as a baseline Mayo score 6 and 12, who were unresponsive to or intolerant to at least one standard therapy, including corticosteroids, immunosuppressants or 5ASAs, were enrolled in ACT 1 (n=364) or ACT 2 (n=364). The 728 patients were randomized to receive REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo at weeks 0, 2, 6 and every subsequent 8 weeks through week 22 (ACT 2) or week 46 (ACT 1). Patients were allowed to continue to receive conventional therapy.

Patients who completed treatment through the final infusion visit and who, in the opinion of the investigator, could benefit from continued treatment with REMICADE could enroll in the extension trials. Across multiple sites, one hundred and eighteen (118) patients were entered into the ACT 1 extension and 111 patients were entered into the ACT 2 extension.

During the extension, patients continued to receive the study drug to which they were originally randomized (REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo) every 8 weeks. Patients in the extension trials were assessed using the Physicians Global Assessment (PGA), which is 1 of 4 measures of disease activity included in the Mayo score. Of the 229 patients who entered the extension, 181 have been followed through one year, and 92 have completed two years. Patients who had responded to placebo also enrolled in

the extension to maintain the blind and continued to receive placebo every 8 weeks.

Overall, REMICADE was generally well tolerated in the long-term extensions, with less than five percent of patients discontinuing therapy due to an adverse event (AE). As previously rep
'/>"/>

Contact: Melissa Katz
215-325-6875
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Roche clinical trial registry and results database launched
2. NIAID begins clinical trial of West Nile virus vaccine
3. Compound might defeat African sleeping sickness, clinical trial beginning this month
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Dalai Lama, top scientists to discuss science & clinical applications of meditation
6. Stem cells electric abilities might help their safe clinical use
7. Clinical trial to test stem cell approach for children with brain injury
8. New malaria vaccine shows promise in early clinical trial
9. Preclinical study of a new brain tumor therapy
10. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
11. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and ... the addition of the "Samsung Galaxy S5 ... report to their offering. ... a totally different sensing technology than the iPhone ... fingerprint sensor in its product. The ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... recent study led by scientists from the National University of ... Spinal Muscular Atrophy (SMA), a devastating disease that is the ... young adults. As there is currently no known cure for ... fight against SMA. SMA is caused by deficiencies ...
... , Dec. 18, 2013 Tissue engineering ... a regenerative or reparative medicine with potential to ... engineering, which involve leveraging technologies from biomaterials, molecular ... the restructure and/or repair of human organs through ...
... have shown for the first time that the specialised role ... cilia tiny hair-like structures protruding from a cell. Stem ... body through the process of differentiation. The discovery ... therapies for a range of medical treatments where scientists aim ...
Cached Biology News:Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 2Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 2State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 4
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 16 BioEnergy International, ... of next-generation, renewable biochemicals and biofuels, announces the ... all of its biobased chemicals business and intellectual ... biofuels opportunities, including its 110 million gallon per ...
... June 16 Wyeth (NYSE: WYE ) (the ... Senior Debentures due 2024 (the "Convertible Debentures") have the right ... to their terms effective on the July 15, 2009 purchase ... in aggregate principal amount of Convertible Debentures outstanding. , ...
... Wound Care Innovations, LLC, a subsidiary of Wound ... reached an agreement in principle to acquire BioPharma Management ... platform of proprietary and patented technologies for topical pain ... structured as a share exchange pursuant to which BioPharma ...
Cached Biology Technology:BioEnergy International, LLC Announces Formation of Myriant Technologies LLC 2Wyeth Announces Holder Right to Surrender Convertible Debentures 2Wyeth Announces Holder Right to Surrender Convertible Debentures 3Wyeth Announces Holder Right to Surrender Convertible Debentures 4Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc. 2
...
... CryoMed Freezers for IVF are designed for ... control, ease of setup and operation, and ... status are continuously displayed on the control ... data are printed by way of the ...
... performance for all vacuum requirements. A 3 ... to suit all applications. The large, sideview ... proper oil levels at a glance. The ... work with all Thermo Savant SpeedVac concentrating ...
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
Biology Products: